Bayer Aktiengesellschaft (OTCMKTS:BAYRY) to Issue Dividend of $0.02

Posted by Jon Anderson on Apr 27th, 2024

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) declared a dividend on Wednesday, April 3rd, NASDAQ reports. Stockholders of record on Tuesday, April 30th will be paid a dividend of 0.0191 per share on Monday, May 13th. The ex-dividend date is Monday, April 29th.

Bayer Aktiengesellschaft Stock Performance

Shares of OTCMKTS BAYRY opened at $7.39 on Friday. Bayer Aktiengesellschaft has a one year low of $6.96 and a one year high of $16.47. The company has a quick ratio of 0.80, a current ratio of 1.27 and a debt-to-equity ratio of 1.15. The business’s fifty day moving average price is $7.40 and its 200-day moving average price is $8.72.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last issued its quarterly earnings results on Tuesday, March 5th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.12. Bayer Aktiengesellschaft had a positive return on equity of 17.27% and a negative net margin of 6.31%. The firm had revenue of $12.77 billion for the quarter. On average, research analysts anticipate that Bayer Aktiengesellschaft will post 1.36 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on BAYRY. Sanford C. Bernstein reissued a “market perform” rating on shares of Bayer Aktiengesellschaft in a report on Thursday, March 7th. Wolfe Research cut Bayer Aktiengesellschaft from an “outperform” rating to a “peer perform” rating in a report on Tuesday, January 30th. Finally, Citigroup reissued a “neutral” rating on shares of Bayer Aktiengesellschaft in a report on Thursday, February 29th. One investment analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold”.

Read Our Latest Report on BAYRY

About Bayer Aktiengesellschaft

(Get Free Report)

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.